Effect of postoperative goal-directed therapy in cancer patients undergoing high-risk surgery: a randomized clinical trial and meta-analysis

Aline Rejane Muller Gerent, Juliano Pinheiro Almeida, Evgeny Fominskiy, Giovanni Landoni, Gisele Queiroz de Oliveira, Stephanie Itala Rizk, Julia Tizue Fukushima, Claudia Marques Simoes, Ulysses Ribeiro Jr, Clarice Lee Park, Rosana Ely Nakamura, Rafael Alves Franco, Patricia Inês Cândido, Cintia Rosa Tavares, Ligia Camara, Graziela dos Santos Rocha Ferreira, Elisangela Pinto Marinho de Almeida, Roberto Kalil Filho, Filomena Regina Barbosa Gomes Galas, and Ludhmila Abrahão Hajjar

Abstract

Background: Perioperative goal-directed hemodynamic therapy (GDHT) has been advocated in high-risk patients undergoing noncardiac surgery to reduce postoperative morbidity and mortality. We hypothesized that using cardiac index (CI)-guided GDHT in the postoperative period for patients undergoing high-risk surgery for cancer treatment would reduce 30-day mortality and postoperative complications.

Methods: A randomized, parallel-group, superiority trial was performed in a tertiary oncology hospital. All adult patients undergoing high-risk cancer surgery who required intensive care unit admission were randomly allocated to a CI-guided GDHT group or to a usual care group. In the GDHT group, postoperative therapy aimed at CI ≥ 2.5 L/min/m² using fluids, inotropes and red blood cells during the first 8 postoperative hours. The primary outcome was a composite endpoint of 30-day all-cause mortality and severe postoperative complications during the hospital stay. A meta-analysis was also conducted including all randomized trials of postoperative GDHT published from 1966 to May 2017.

Results: A total of 128 patients (64 in each group) were randomized. The primary outcome occurred in 34 patients of the GDHT group and in 28 patients of the usual care group (53.1% vs 43.8%, absolute difference 9.4 (95% CI, –7.8 to 25.8); p = 0.3). During the 8-h intervention period more patients in the GDHT group received dobutamine when compared to the usual care group (55% vs 16%, p < 0.001). A meta-analysis of nine randomized trials showed no differences in postoperative mortality (risk ratio 0.85, 95% CI 0.59–1.23; p = 0.4; p for heterogeneity = 0.7; I² = 0%) and in the overall complications rate (risk ratio 0.88, 95% CI 0.71–1.08; p = 0.2; p for heterogeneity = 0.07; I² = 48%), but a reduced hospital length of stay in the GDHT group (mean difference (MD) –1.6; 95% CI –2.75 to –0.46; p = 0.006; p for heterogeneity = 0.002; I² = 74%).

(Continued on next page)
Conclusions: CI-guided hemodynamic therapy in the first 8 postoperative hours does not reduce 30-day mortality and severe complications during hospital stay when compared to usual care in cancer patients undergoing high-risk surgery.

Trial registration: www.clinicaltrials.gov, NCT01946269. Registered on 16 September 2013.

Keywords: Goal-directed therapy, Cancer, High-risk surgery, Mortality, Randomized clinical trial, Meta-analysis

Background
For many patients with solid tumors, surgery remains the mainstay of therapy. For these patients, a complication-free operative procedure is vital to maximize the chances that oncological treatment is successful. Postoperative care of cancer patients having major abdominal surgery is challenging because of the unusually long duration of the surgical procedures, the significant fluid and blood losses that can occur, the inherent immunological disturbances and the increased operative risk, as demonstrated by previous studies [1, 2].

Goal-directed hemodynamic therapy (GDHT) comprising rational use of fluids, inotropes, vasopressors and red blood cell (RBC) transfusion according to hemodynamic targets to improve oxygen delivery (DO₂) can provide outcome benefits in high-risk patients [3]. Even if some studies suggested that GDHT in high-risk patients undergoing surgery was associated with a significant reduction in morbidity and mortality [4–6], recent evidence suggests that the benefits are less than previously hypothesized because of the potential harm of fluid overload, drugs side effects and invasive monitoring [7, 8].

In addition, in most studies GDHT was investigated during surgery and extending for the first 6–12 h after intensive care unit (ICU) admission. It is unclear whether the potential benefits of GDHT are present when GDHT is used during the whole perioperative period or if GDHT use only in the postoperative ICU setting might result in clinical benefits or even in harmful interventions.

Therefore, we performed a randomized clinical trial (RCT) to evaluate the effects of a postoperative GDHT protocol on a composite endpoint of 30-day all-cause mortality and severe postoperative complications during the hospital stay in high-risk cancer patients undergoing surgery. We also conducted an updated systematic review focusing on postoperative GDHT and incorporating the findings of this trial.

Methods
The Goal-Directed Resuscitation in Cancer Surgery (GRICS II) trial was a single-center, parallel and randomized trial performed at the Cancer Institute, University of Sao Paulo, Sao Paulo, Brazil. The study was approved by the Faculty of Medicine Ethics Committee (number 335/13). This trial was registered at ClinicalTrials.gov on September 16, 2013 (NCT01946269). Written informed consent was obtained from all subjects or their legal surrogates prior to enrolment in the study. Patients were enrolled from October 2013 to September 2015. The trial was overseen by an independent data and safety monitoring board. The two funding sources were the University of Sao Paulo (Brazil) and Edwards LTDA (Irvine, CA, USA), which had no other role in the study. All the authors vouch for the fidelity of the study to the trial protocol and for the accuracy of the data and data analyses.

Participants
Consecutive patients who were 18 years old or more and scheduled for cancer surgery at the Cancer Institute were screened for enrolment. Patients undergoing high-risk surgery for cancer treatment (upper and lower gastrointestinal tract, urogenital tract, liver or biliary tract surgeries) with duration longer than 90 min and requiring ICU admission were included in the study. Patients were excluded from the study if one of the following was present: declined consent; emergency surgery; enrolled in another study; weight under 55 kg or over 140 kg; active bleeding; contraindication to invasive hemodynamic monitoring; hemodynamic instability (norepinephrine higher than 1 μg/kg/min); surgery for palliative treatment only; or presence of cardiac arrhythmia (atrial fibrillation, frequent ectopy or other dysrhythmias).

Randomization
Randomization was performed, with a computer-generated list in a 1:1 ratio generated online by a web-based program that ensured allocation concealment.

The investigator opened the serially numbered, sealed, opaque envelopes on arrival of the patients at the ICU, provided exclusion criteria were not met. The nature of the intervention precluded blinding of the patients and attending physicians. Outcome assessors were unaware of the assigned treatment.

The decision to admit the patients to the ICU was made by clinical staff and registered before randomization and surgery.

Study treatments
All patients
Anesthetic management and perioperative care of patients were standardized and are described in detail in
Additional file 1: Appendix 1. Briefly, all patients were monitored with a central venous line and indwelling radial artery catheter. Fluids, vasopressor and inotropic agents were administered to maintain mean arterial pressure (MAP) ≥65 mmHg, urinary output >0.5 ml/kg/h, oxygen venous saturation ≥70% and lactate levels <3 mmol/L. Preload was optimized by fluid loading until pressure pulse variation (PPV) was <10%. Interventions included fluid resuscitation with lactated Ringer’s preferentially, administration of dobutamine and RBC transfusion if needed according to hemodynamic data.

After ICU admission, all patients received care to keep adequate temperature (36 °C), oxygen saturation ≥95%, MAP ≥ 65 mmHg, heart rate (HR) between 70 and 100 bpm, central venous oxygen saturation (ScvO₂) >70%, lactate level < 3 mmol/L, urinary output > 0.5 ml/kg/h and normoglycemia (140–180 mmol/L). Additional fluids and vasoactive drugs could be administered by the physicians guided by HR, MAP, urine output, venous central oxygen saturation, serum lactate and base excess. Analgesia was provided in most cases by epidural infusion. In a few cases when an epidural technique was not possible, intravenous infusion of morphine was performed.

**GHDT group**

A cardiac output monitor - Vigileo - Edwards LTDA (Irvine, CA, USA) was connected to the radial artery and the cardiac index (CI) and stroke volume index (SVI) values were used as goals to deliver the hemodynamic intervention.

The protocol started at ICU admission and lasted 8 h. The main goal was to achieve CI ≥2.5 L/min/m². Initially, fluid resuscitation was provided with the administration of an intravenous bolus in 15 min of 200 ml of Ringer lactate solution with 50 ml of 20% albumin solution if the SVI was less than 35 ml/m². Fluid administration was repeated accordingly to responsiveness and interrupted if SVI ≥ 35 ml/m². The definition of positive response to fluid challenge was an increase in cardiac index ≥ 15% from baseline.

If the CI remained < 2.5 L/min/m², dobutamine infusion was started at 3 μg/kg/min and titrated every 15 min up to a maximum dose of 20 μg/kg/min. If these interventions did not result in CI ≥ 2.5 L/min/m², RBCs were transfused 1 unit at a time to achieve hematocrit > 24% (Fig. 1).

**Usual care group**

For patients in the usual care group, the institutional protocol was followed to achieve HR between 70 and 100 bpm, ScvO₂ >70%, lactate level < 3 mmol/L, hematocrit value > 28%, MAP ≥ 65 mmHg and urinary output > 0.5 ml/kg/h through fluid resuscitation with Ringer lactate solution, administration of dobutamine and RBC transfusion.

**Study outcomes**

The primary endpoint was a composite endpoint of 30-day mortality and major clinical complications (Additional file 1: Appendix 2) during the hospital stay. Clinical complications were acute kidney injury (AKI), stroke, myocardial infarction, acute decompensated heart failure, pulmonary thromboembolism, mesenteric ischemia, peripheral vascular ischemia, acute respiratory distress syndrome (ARDS), deep wound infection and reoperation.

Secondary endpoints included the incidence of septic shock, development of AKI requiring renal replacement therapy (RRT), ICU readmission rate, ICU and hospital lengths of stay (LOS), 7-day sepsis-related organ failure assessment (SOFA) score and 90-day mortality (Additional file 1: Appendix 2).

We also analyzed the following hemodynamic parameters and perfusion indexes during the intervention period (at 0 h, 2 h, and 8 h): HR, MAP, ScvO₂, lactate levels, base excess and CO₂ gap.

**Data collection and definition of complications**

Data were collected by two blinded assessors with more than 3 years of work experience in the cancer ICU. Patients were discharged from the ICU if their physiologic status was stable, there was no need for monitoring and active interventions were not planned. Follow-up after hospital discharge was performed by telephone on the 30th postoperative day (Additional file 1: Appendix 3).

**Systematic review**

We also conducted a meta-analysis of all published RCTs following the PRISMA guidelines and comparing postoperative GDHT with standard therapy in noncardiac surgery adult high-risk patients. The PubMed/Medline, Embase and Scopus databases were searched from inception up to May 1, 2017. Details on the PubMed search strategy are provided in Additional file 1: Appendix 4. Two researchers independently screened the titles and abstracts of all initially identified studies according to the selection criteria and extracted the required data. Consensus was reached in the case of any inconsistency with involvement of a third author. We included only studies reporting mortality data (primary outcome of the meta-analysis). Secondary endpoints were overall complications rate and hospital length of stay. Detailed methods are described in Additional file 1: Appendix 4.

**Statistical analysis**

Considering a two-sided alpha level of 0.05 and a statistical power of 90%, we calculated that a sample size of
128 patients would be required to reduce the incidence of the composite endpoint from 56% in the control group to 28% in the GDHT group [5]. All analyses were conducted according to the intention-to-treat principle. No assumptions were made for missing or unavailable data. We report continuous variables as mean with standard deviation (SD) or median with interquartile range (IQR), and categorical variables as proportions. Continuous variables were compared using a Student’s t test or Mann–Whitney U test and categorical variables using Pearson χ² or Fisher exact or likelihood ratio test. Comparisons of SOFA score over time were made using nonparametric Friedman test. Kaplan–Meier curves were built for event-free survival probability up to 30 days following surgery. Two-sided p < 0.05 was considered statistically significant.

For the meta-analysis, treatment effects were reported as risk ratio (RR) with 95% confidence interval (CI) for mortality and complications or mean differences with standard deviations for hospital length of stay. The Mantel–Haenszel method was used to combine summary measures using a random-effects model. We evaluated heterogeneity between studies using Cochran’s Q and the I² statistic. We assessed the potential of publication bias through funnel plot generation and Egger’s regression test.

SPSS version 18.0 (SPSS Inc., Chicago, IL, USA), Review Manager (RevMan, Version 5.3, 2014; The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark) and STATA (Version 11; StataCorp, College Station, TX, USA) were used for all statistical analyses.

**Results**

**Study population**

One hundred and twenty-eight patients were included in the study (Fig. 2). All patients had outcome data collected and completed the follow-up. Patients were 67 years old and had a good performance status prior to surgery (Table 1), the most commonly performed being gastrointestinal followed by liver and biliary tract surgery. The groups were similar regarding the
intraoperative amount of fluids, vasoactive drugs and RBC transfusion received (Table 2).

**Intervention period**

In the first 8 h after ICU admission, there was no difference between groups in the volume of administered fluids (1195 ± 719 ml GDHT group vs 1290 ± 609 ml usual care group, $p = 0.4$) and in the RBC transfusion rate (3.1% GDHT group vs 0% usual care group, $p = 0.5$). There was a higher use of dobutamine in the GDHT group when compared to the usual care group (35 patients (55%) vs 10 patients (15%), $p < 0.001$). The CI of the GDHT group patients during the 8-h intervention is reported in Additional file 1: Figure S1. There were no differences between groups in the hemodynamic parameters or perfusion indexes (HR, MAP, ScvO$_2$, lactate levels, base excess and PCO$_2$ gap; Table 3).

**Primary outcome**

The primary composite endpoint of 30-day all-cause mortality and severe clinical complications occurred in 34 patients (53%) in the GDHT group and in 28 patients (44%) in the usual care group ($p = 0.3$). No significant differences were observed between the GDHT and usual care groups in the rate of mortality (14% vs 9%, $p = 0.4$) and of the other severe complications (Table 4), with AKI (51% vs 39%, $p = 0.184$) and reoperation (8% vs 5%, $p = 0.7$) being the most frequently represented.

**Secondary outcomes**

We did not observe significant differences in any of the secondary outcomes between the GDHT and usual care groups: septic shock (16% vs 13%, $p = 0.6$), AKI needing RRT (13% vs 8%, $p = 0.4$), ICU readmission (13% vs 9%, $p = 0.6$), ICU stay (3 (2–8) days vs 3 (2–5) days, $p = 0.6$) and hospital LOS (11 (6–19) days vs 10 (6–15) days, $p = 0.4$; Table 5).

**Meta-analysis**

Our searches identified 1528 records. After screening based on titles and abstracts, eight articles remained for full-text assessment (Additional file 1: Figure S2). All of them met the inclusion criteria and were included in the systematic review [4, 9–15]. Details of the key characteristics of the trials are presented in Additional file 1: Table S1. Seven RCTs included more than 100 patients [4, 9, 12, 15] and one trial was multicenter [9]. The clinical settings were cardiac surgery in four trials [10, 11, 13, 15], general surgery in three studies [4, 9, 12] and hepatic surgery in one trial. The duration of the GDHT varied from 4 to 12 h. Fluids and inotropic support were used within the GDHT protocol in all included studies, while some of the RCTs also used RBC transfusion and vasodilators. Most included trials were categorized as at low risk of bias (Additional file 1: Table S2 and Figure S3).
There were no differences in the longest follow-up mortality between groups (RR 0.85, 95% CI 0.59–1.23; \( p \) for effect = 0.4; \( p \) for heterogeneity = 0.7; \( I^2 = 0\); eight included trials; Fig. 3a) and overall complication rate (RR 0.88, 95% CI 0.71–1.08; \( p \) for effect = 0.2; \( p \) for heterogeneity = 0.07; \( I^2 = 48\%\); seven included trials; Fig. 3b). The lack of a GDHT effect on the overall complication rate was confirmed when sequentially removing included trials (Additional file 1: Table S3). GDHT reduced hospital LOS (MD –1.6; 95% CI –2.75 to –0.46; \( p \) for effect = 0.006; \( p \) for heterogeneity = 0.002; \( I^2 = 74\%\); six included trials; Fig. 3c).

**Discussion**

The main finding of this RCT is that among cancer patients undergoing high-risk surgery, the use of CI-guided

### Table 1 Baseline and demographic patients’ characteristics

| Variable | GDHT group \((n = 64)\) | Usual care group \((n = 64)\) |
|----------|-----------------|-----------------|
| Age (years), mean ± SD | 66 ± 12 | 68 ± 11 |
| BMI (kg/m²), median (IQR) | 25 (21–31) | 25 (21–30) |
| Sex (male), n (%) | 32 (50%) | 37 (58%) |
| Race (white), n (%) | 48 (75%) | 52 (81%) |
| Charlson score\(^a\), median (IQR) | 5 (4–6) | 6 (5–8) |
| ECOG score\(^b\), n (%) | | |
| 0 | 29 (47%) | 26 (43%) |
| 1 | 19 (31%) | 19 (32%) |
| 2 | 6 (10%) | 8 (13%) |
| 3 | 8 (13%) | 6 (10%) |
| 4 | 0 | 1 (2%) |
| Karnofsky score\(^c\), median (IQR) | 90 (80–100) | 90 (80–100) |
| Neoplasm, n (%) | | |
| Stomach | 0 | 1 (2%) |
| Esophagus | 9 (13%) | 6 (10%) |
| Colon–rectus | 8 (13%) | 6 (10%) |
| Gynecological | 18 (30%) | 21 (34%) |
| Pancreas | 9 (15%) | 9 (15%) |
| Liver | 6 (10%) | 2 (3%) |
| Prostate | 6 (10%) | 8 (13%) |
| Kidney | 4 (7%) | 5 (8%) |
| Others | 1 (2%) | 3 (5%) |
| Recent chemotherapy, n (%) | 3 (5%) | 1 (2%) |
| Recent radiotherapy, n (%) | 0 | 0 |
| Smokers, n (%) | | |
| No | 41 (64%) | 41 (64%) |
| Yes | 9 (14%) | 7 (11%) |
| Previously | 14 (22%) | 16 (25%) |
| Alcoholism, n (%) | | |
| No | 56 (88%) | 55 (86%) |
| Yes | 4 (6%) | 2 (3%) |
| Previously | 4 (6%) | 7 (11%) |
| Hypertension, n (%) | 38 (59%) | 35 (53%) |
| Diabetes mellitus, n (%) | 12 (19%) | 16 (25%) |
| Heart failure, n (%) | 2 (3%) | 3 (5%) |
| Chronic obstructive pulmonary disease, n (%) | 4 (6%) | 6 (9%) |
| Chronic kidney disease, n (%) | 2 (3%) | 6 (9%) |
| Hypothyroidism, n (%) | 5 (8%) | 4 (6%) |
| Stroke, n (%) | 0 | 6 (9%) |

**Table 2 Surgical-related characteristics**

| Variable | GDHT group \((n = 64)\) | Usual care group \((n = 64)\) |
|----------|-----------------|-----------------|
| Surgery type, n (%) | | |
| Upper gastrointestinal tract | 21 (33%) | 13 (20%) |
| Lower gastrointestinal tract | 15 (23%) | 14 (22%) |
| Liver and biliary tract | 2 (3%) | 5 (8%) |
| Urogenital tract | 15 (23%) | 22 (34%) |
| Others | 11 (17%) | 10 (16%) |
| Duration of surgery (min), median (IQR) | 360 (273–480) | 300 (240–435) |
| Fluids (ml), median (IQR) | 4000 (3000–5763) | 4000 (3000–5225) |
| Norepinephrine, n (%) | 20 (31%) | 19 (30%) |
| Dobutamine, n (%) | 0 | 4 (6%) |
| Vasopressin, n (%) | 1 (2%) | 0 |
| RBC transfusion, n (%) | 19 (30%) | 15 (23%) |
| Fresh frozen plasma, n (%) | 2 (3%) | 2 (3%) |
| Cryoprecipitate, n (%) | 0 | 1 (2%) |
| Platelets, n (%) | 1 (2%) | 0 |

GDHT goal directed hemodynamic therapy, IQR interquartile range, RBC red blood cell
hemodynamic therapy applied in the first 8 postoperative hours is not associated with a reduction in 30-day mortality and severe postoperative complications when compared with protocolized hemodynamic therapy incorporating measures of perfusion and intraoperative PPV. The GDHT resulted in a higher exposure of the patients to dobutamine, without improving outcomes. After including the results of this trial in an updated systematic review and meta-analysis, we confirmed that the strategy of postoperative GDHT does not reduce overall complications and mortality in high-risk surgical patients. However, the meta-analysis suggested that postoperative GHDT is associated with a lower length of hospital stay.

GDHT is recommended in the context of enhanced recovery programs in high-risk patients [16]. A recent published meta-analysis including 45 RCTs suggested that the use of GDHT in major abdominal surgery reduces mortality and overall complications [6]. Our meta-analysis differs from this previous one because we included RCTs with a GDTH protocol performed exclusively after surgery, in the ICU. Most studies included in the meta-analysis by Sun et al. [6] start the protocol during surgery and extend it to the first 8 h of the postoperative period.

Interestingly, the best timing for performing GDHT is not specified in previous systematic reviews and recommendations. The majority of studies defined the interventions as “perioperative”, including the surgical room period and the first 6–12 h of postoperative care. We therefore speculate that most of the benefits of the GDH protocol, if any, are the result of intraoperative protocols. Our study demonstrates that a GDHT postoperative protocol does not add benefits in outcomes when compared to a usual care protocol and might be associated with over therapy without improving outcomes.

The updated meta-analysis including nine randomized studies confirmed no reduction in mortality and overall complications while suggesting that the benefits of postoperative GDHT might be limited to a reduction in the length of hospital stay. This brings to the discussion whether it is necessary to apply postoperative GDHT in high-risk patients already undergoing an intraoperative protocol of cardiac output-guided hemodynamic algorithm as we did in our patients.

Our study differs from previous ones performed in noncardiac surgery [3–5, 7]. First, the usual care group received multimodal hemodynamic care based on the optimization of hemodynamic parameters and tissue perfusion markers, which may be enough for adequate oxygen delivery during the postoperative period. Second, during anesthesia, patients were monitored with a central venous line and an arterial line, and hemodynamic variables such as PPV, ScvO2 and arterial lactate were evaluated in protocolized care. Thus, it is possible that occult tissue hypoperfusion and hypoxia were avoided in the subsequent 8 h of the intervention. This is confirmed by the observation that the majority of patients were admitted to the ICU with CI > 2.5 L/min/m².

In septic shock patients, Rivers et al. [17] demonstrated that goal-directed therapy aiming at adequate ScvO2 reduced mortality. In the last years, with advances in the process of care, more recent studies have not confirmed the benefits of applying GDHT in the ICU in septic patients [18].

The largest study evaluating the impact of cardiac output-guided hemodynamic therapy in surgical

---

### Table 3 Hemodynamic variables and tissue perfusion markers during 8-h intervention period

| Variable                  | GDHT group (n = 64) | Usual care group (n = 64) | p     |
|---------------------------|---------------------|--------------------------|-------|
| ΔPCO2 (%)                 |                     |                          | 0.9   |
| 0 h                       | 6.8 ± 4.4           | 6.8 ± 4.9                |       |
| 2 h                       | 7.5 ± 5.8           | 6.9 ± 4.7                |       |
| 8 h                       | 6.0 ± 3.3           | 6.8 ± 4.2                |       |
| BE (mmol)                 |                     |                          | 0.9   |
| 0 h                       | −3.7 ± 2.9          | −3.7 ± 3.0               |       |
| 2 h                       | −4.1 ± 3.7          | −3.4 ± 2.9               |       |
| 8 h                       | −2.4 ± 2.7          | −2.9 ± 3.0               |       |
| Lactate (mmol/L)          |                     |                          | 0.9   |
| 0 h                       | 2.6 ± 1.5           | 2.8 ± 2.3                |       |
| 2 h                       | 2.9 ± 2.0           | 3.0 ± 2.3                |       |
| 8 h                       | 2.9 ± 1.8           | 3.0 ± 2.5                |       |
| HR (bpm)                  |                     |                          | 0.9   |
| 0 h                       | 83.1 ± 21.6         | 85.5 ± 23.9              |       |
| 2 h                       | 829.7 ± 20.7        | 839.2 ± 22.6             |       |
| 8 h                       | 882.2 ± 21.3        | 849.8 ± 18.9             |       |
| MAP (mmHg)                |                     |                          | 0.3   |
| 0 h                       | 94.5 ± 19.6         | 91.6 ± 17.8              |       |
| 2 h                       | 88.1 ± 15.6         | 87.3 ± 14.7              |       |
| 8 h                       | 85.3 ± 16.9         | 82.1 ± 15.2              |       |
| ScvO2 (%)                 |                     |                          | 0.2   |
| 0 h                       | 75.7 ± 9.0          | 77.1 ± 9.0               |       |
| 2 h                       | 75.6 ± 8.7          | 77.4 ± 6.6               |       |
| 8 h                       | 78.7 ± 6.6          | 76.4 ± 8.0               |       |
| CI (L/min/m²)             |                     |                          |       |
| 0 h                       | 2.9 ± 1.0           | –                        |       |
| 2 h                       | 2.9 ± 0.9           | –                        |       |
| 8 h                       | 3.1 ± 1.0           | –                        |       |

Data expressed as mean ± standard deviation
GDHT goal-directed hemodynamic therapy, ΔPCO2 dioxide carbon gap, BE base excess, HR heart rate, MAP mean arterial pressure, ScvO2 central venous oxygen saturation, CI cardiac index
patients, the OPTIMISE trial, included 734 patients undergoing major abdominal surgery in 17 different centers. This study did not show any benefits in the intervention group for postoperative complications and mortality reduction over standard therapy [7].

In our GDHT group, patients needed more dobutamine, but we did not observe a higher risk of arrhythmia or myocardial injury, as confirmed by previous trials [7, 19]. Our GDHT protocol of care did not result in either more prescribed fluids or red blood cells, maybe because most patients were already adequately resuscitated during the intraoperative period.

We used albumin solution in the algorithm of treatment because colloid solutions are superior when compared to crystalloids in reaching hemodynamic goals [20]. In addition, previous randomized clinical studies in critically ill patients showed the safety of albumin solutions [21, 22].

We chose to use a minimally invasive noncalibrated device to measure the cardiac index. Although this device has its accuracy reduced when compared to other calibrated devices, the data are reproducible, easy to measure and easy to interpret and it is used in both surgical rooms and ICUs. In addition, physicians and nurses were already trained. We selected a cardiac index target of 2.5 L/min/m² based on a previous study that was able to demonstrate improved outcomes in high-risk patients using a similar target [12].

Our study has limitations. Due to the nature of the intervention protocol, blinding was not feasible, and to

### Table 4 Primary outcome

| Variable                        | GDHT group (n = 64) | Usual care group (n = 64) | Absolute difference (95% CI) | p     |
|---------------------------------|---------------------|--------------------------|------------------------------|-------|
| Composite endpoint              | 53 (40–66)          | 44 (31–57)               | 9.4 (~7.8 to 25.8)           | 0.3   |
| Mortality                       | 14 (7–25)           | 9 (4–19)                 | 4.7 (~6.9 to 16.4)           | 0.4   |
| Stroke                          | 0 (0–6)             | 2 (0–8)                  | −1.6 (~8.3 to 4.2)           | 0.9   |
| AKI                             | 51 (36–61)          | 39 (27–52)               | 9.4 (~7.6 to 25.6)           | 0.2   |
| ARDS                            | 5 (2–15)            | 2 (0–8)                  | 4.7 (~3.1 to 13.5)           | 0.4   |
| Acute myocardial infarction     | 2 (0–8)             | 5 (0.9–13)               | −3.1 (~11.4 to 4.3)          | 0.6   |
| Acute heart failure             | 0 (0–6)             | 2 (0–8)                  | −1.6 (~8.3 to 4.2)           | 0.5   |
| Mesenteric ischemia             | 2 (0–8)             | 0 (0–6)                  | 1.6 (~4.2 to 8.3)            | 0.9   |
| Peripheral vascular ischemia    | 0 (0–6)             | 3 (0.3–11)               | −3.1 (~10.7 to 3.0)          | 0.5   |
| Pulmonary embolism              | 0 (0–6)             | 0 (0–6)                  | −                      | −     |
| Deep wound infection            | 3 (0.3–11)          | 8 (3–17)                 | −4.7 (~14.2 to 4.1)          | 0.4   |
| Reoperation                     | 8 (3–17)            | 5 (0.9–13)               | 3.1 (~6.2 to 12.8)           | 0.7   |

Data presented as % (95% CI)

GDT goal-directed hemodynamic therapy, CI confidence interval, AKI acute kidney injury, ARDS acute respiratory distress syndrome

### Table 5 Secondary outcomes

| Variable                          | GDHT group (n = 64) | Usual care group (n = 64) | Absolute difference (95% CI) | p     |
|-----------------------------------|---------------------|--------------------------|------------------------------|-------|
| Septic shock                      | 16 (8–27)           | 13 (6–23)                | 3.1 (~9.3 to 15.5)           | 0.611 |
| AKI AKIN 3 and RRT                | 13 (6–23)           | 8 (3–17)                 | 4.7 (~6.3 to 15.9)           | 0.380 |
| ICU readmission                   | 13 (6–23)           | 9 (4–19)                 | 3.1 (~8.2 to 14.6)           | 0.571 |
| Length of ICU stay (days), median | 3 (2–8)             | 3 (2–5)                  | −                            | 0.571 |
| Length of hospital stay (days),   | 11 (6–19)           | 10 (6–15)                | −                            | 0.354 |
| median (IQR)                      | (IQR)               |                          |                              |       |
| SOFA score, mean ± SD             | 4.3 ± 2.4           | 3.6 ± 2.2                | −0.7 (~1.5 to 0.1)           | 0.308 |
| 1                                 | 4.0 ± 2.5           | 3.2 ± 2.3                | −0.8 (~1.6 to 0)             |       |
| 2                                 | 2.8 ± 2.8           | 2.1 ± 2.2                | −0.7 (~1.6 to 0.2)           |       |

Data presented as % (95% CI)

GDT goal-directed hemodynamic therapy, CI confidence interval, AKI acute kidney injury, AKIN Acute Kidney Injury Network, RRT renal replacement therapy, ICU intensive care unit, IQR interquartile range, SOFA Sequential Organ Failure Assessment, SD standard deviation, D1 first day postoperative, D2 second day postoperative
reduce potential bias, outcome assessors were not aware of the study group assignment. Our results may have limited external validity because this was a single-center trial conducted in a cancer reference hospital. In addition, we analyzed a conventional hemodynamic perioperative protocol based on “normal” values of variables such as cardiac index (CI) and systolic volume. However, we have learned that population-based “normal” values do not necessarily represent the optimal values or the personal normal values of an individual. It is known that many hemodynamic variables have marked interindividual variability and depend on other factors such as biometric factors and time of disease, and probably using fixed hemodynamic goals might have contributed to the negative results of this trial. We postulate that the best concept to be applied at the bedside in high-surgical risk patients is personalized hemodynamic management, based on adaptive multiparameter hemodynamic optimization strategies targeting individual normal values adapted to the clinical situation [23–25].

This was a pragmatic study designed to analyze the effect of GDHT in the postoperative scenario of the ICU. We aimed to assess the postoperative period separately because in usual practice, independently of intraoperative management, the hemodynamic algorithm continues to be applied routinely during the first hours in the ICU. We evaluated whether applying a fixed GDHT algorithm in the postoperative period might contribute to reduce complications or even results in harm. Our results bring into discussion the need for a more personalized approach at this point, once we have shown that there is no benefit of postoperative GDHT in cancer patients undergoing major surgeries. The updated meta-analysis confirms that postoperative GDHT does not reduce overall complications and death, but might be associated with a reduced length of hospital stay.

**Conclusions**

A cardiac index-guided hemodynamic therapy applied in the first 8 postoperative hours in cancer patients undergoing high-risk surgery did not reduce 30-day mortality and the rate of postoperative complications when compared with protocolized hemodynamic therapy including measures of perfusion and intraoperative PPV. This therapy was associated with an increased use of dobutamine without improving outcomes.
The authors declare that they have no competing interests.

Ethics approval and consent to participate

The study was approved by the Faculty of Medicine Ethics Committee (number 335/13). Written informed consent was obtained from all subjects or their legal surrogates prior to enrolment in the study.

Competing interests

The authors declare that they have no competing interests.

Abbreviations

AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome; CI: Cardiac index; DO₂: Oxygen delivery; GDHT: Goal-directed hemodynamic therapy; HR: Heart rate; ICU: Intensive care unit; IQR: Interquartile range; MAP: Mean arterial pressure; RBC: Red blood cell; RCT: Randomized clinical trial; RR: Risk ratio; RRT: Renal replacement therapy; ScvO₂: Central venous oxygen saturation; SD: Standard deviation; SOFA: Sepsis-related organ failure assessment; SVI: Stroke volume index.

Funding

The two funding sources were the University of Sao Paulo (Brazil) and Edwards LTDA (Irvine, CA, USA), which had no other role in the study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Authors’ contributions

ARMG had full access to all of the data and takes responsibility for the integrity of the data and the accuracy of the data analysis. ARMG, JPA, FRBGG and LAH contributed to study concept and design. All authors contributed to acquisition, analysis or interpretation of data. EPMdA, ARMG, JPA, FRBGG, LAH, EF and GL drafted the manuscript. EPMdA, ARMG, JPA, FRBGG, LAH, EF, GL and UR contributed to critical revision of the manuscript for important intellectual content. JTF and EF performed statistical analysis. ARMG, EF, CMS and CLP contributed administrative, technical or material support. ARMG and LAH were responsible for study supervision. All authors agreed to be accountable for all aspects of the work, thereby ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

The study was approved by the Faculty of Medicine Ethics Committee (number 335/13). Written informed consent was obtained from all subjects or their legal surrogates prior to enrolment in the study.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. de Almeida JP, Vincent JL, Galas FR, et al. Transfusion requirements in cancer patients undergoing high-risk surgery: a prospective, randomized controlled trial. Anesthesiology. 2015;122:29–38.
2. Sankar A, Beattie WS, Wijesundara DN. How can we identify the high-risk patient? Curr Opin Crit Care. 2015;21:328–35.
3. Tote SP, Grounds RM. Performing perioperative optimization of the high-risk surgical patient. Br J Anaesth. 2006;97:4–11.
4. Jhanji S, Vivian-Smith A, Lucena-Amaro S, Watson D, Hinds CJ, Pearse RM. Haemodynamic optimisation improves tissue microvascular flow and oxygenation after major surgery: a randomised controlled trial. Crit Care. 2010;14:R151.
5. Beres J, Chytra I, Altmann P, et al. Intraoperative fluid utilization in high risk surgical patients: results of prospective randomized study. Crit Care. 2010;14:R118.
6. Sun Y, Chai F, Pan C, Remeiser JL, Gan TJ. Effect of perioperative goal-directed hemodynamic therapy on postoperative recovery following major abdominal surgery—a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2017;21:141.
7. Pease RM, Harrison DA, MacDonald N, et al. Effect of a perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes following major gastrointestinal surgery: a randomized clinical trial and systematic review. JAMA. 2014;311(21):2181–90.
8. Grocott MP, Dushiantan A, Hamilton MA, et al. Perioperative increase in global blood flow to explicit defined goals and outcomes following surgery. Cochrane Database Syst Rev. 2012;11:CD004082.
9. Ackland GL, Iqbal S, Paredes LG, et al. Individualised oxygen delivery targeted haemodynamic therapy in high-risk surgical patients: a multicentre, randomised, double-blind, controlled, mechanistic trial. Lancet Respir Med. 2015;3:33–41.
10. Gómez-Coronado VI, Marcos MR, Cxventos DP, et al. Hemodynamic optimization and morbimortality after heart surgery. Med Int. 2001;25:297–302.
11. Kapoor PM, Kakani M, Chowdhury U, Chowdhury M, Lakshmy, Kiran U. Early goal-directed therapy in moderate to high-risk cardiac surgery patients. Ann Card Anaesth. 2008;11:27–34.
12. Pease R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early goal-directed therapy after major surgery reduces complications and duration of hospital stay. A randomised, controlled trial [ISRCTN38797445]. Crit Care. 2005;9:R86–93.
13. Polonen P, Ruokonen E, Hippielainen M, Poyhonen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg. 2002;90:1052–9.
14. Ueno S, Tanabe G, Yamada H, et al. Response of patients with cirrhosis who have undergone partial hepatectomy to treatment aimed at achieving supranormal oxygen delivery and consumption. Surgery. 1998;123:278–86.
15. McKendry M, McGiln H, Saberi D, Caudwell L, Brady AR, Singer M. Randomised controlled trial assessing the impact of a nurse delivered, flow monitored protocol for optimisation of circulatory status after cardiac surgery. BMJ. 2004;329:258.
16. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg. 2011;112:1392–402.
17. Riviére E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.
18. PRISM Investigators, Rowan KM, Angus DC, et al. Early, goal-directed therapy for septic shock—a patient-level meta-analysis. N Engl J Med. 2017;376:2223–34.
19. Osawa EA, Rhodes A, Iandoli G, et al. Effect of perioperative goal-directed hemodynamic resuscitation therapy on outcomes following cardiac surgery: a randomized clinical trial and systematic review. Crit Care Med. 2016;44:724–33.
20. Feldheiser A, Pavlova V, Bonomo T, et al. Balanced colloidal solution using a goal-directed haemodynamic algorithm. Br J Anaesth. 2013;110:231–40.
21. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–56.
22. Caironi P, Tognoni G, Masson S, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412–21.
23. Saugel B, Vincent JL, Wagner JY. Personalized hemodynamic management. Curr Opin Crit Care. 2017;23:334–41.
24. Molnar Z, Szabo Z, Nemeth M. Multimodal individualized concept of hemodynamic monitoring. Curr Opin Anaesthesiol. 2017;30:171–7.
25. Ince C. Personalized physiological medicine. Crit Care. 2017;21:308.